cebo. Although Cmax and tmax tended to be higher in the placebo group, thepairwise comparisons between place-bo and each exenatide dose were notsignificantly different ( p > 0.05), ex- cept for the comparison of t max be- tween the placebo and 0.3- µg/kg ex- enatide groups ( p = 0.0213).Table 2. Demographic and Baseline Characteristics of Patients (Intent-to- Treat Population) Study A ( n = 8) Part 1 ( n = 6) No. male Race, no. CaucasianOther Mean  ± S.D. age (yr) Mean ± S.D. weight (kg) Mean ± S.D. BMI (kg/m2) Mean ± S.D. HbA1c (%)   8    1    7 53  ± 10 88.5 ± 9.4 29.5 ± 2.8 9.5 ± 1.62 4 2  56 ± 5 86.3 ± 15.4 32.5 ± 6.5 8.4 ± 1.0Characteristica  5  7  1  52 ± 8 88.8 ± 12.1 28.6 ± 5.0 7.6 ± 1.6Part 2 ( n = 8)Study B aBMI = body mass index, HbA1c = glycosylated hemoglobin.